Alkermes, Inc., a biotechnology company, develops products based on proprietary, extended-release and pulmonary drug delivery technologies. It has two commercial products that include RISPERDAL CONSTA, a long-acting atypical antipsychotic medication approved for use in schizophrenia, marketed worldwide by Janssen-Cilag; and VIVITROL, a once-monthly injectable medication approved for the treatment of alcohol dependence, marketed in the U.S. primarily by Cephalon, Inc. The company's pipeline comprises extended-release injectable, pulmonary, and oral products for the treatment of prevalent and chronic diseases, such as central nervous system disorders, addiction, and diabetes. Its development programs also include AIR Insulin, which is in Phase III clinical development stage for the treatment of diabetes; Exenatide LAR, a Phase II clinical development stage product for the treatment of type 2 diabetes; a Phase I/II clinical study product, ALKS 29, for the treatment of alcohol dependence; a Phase IIa clinical study product, ALKS 27, for the treatment of COPD, which is a serious, chronic disease characterized by a gradual loss of lung function; and AIR parathyroid hormone, a Phase I clinical study product for the treatment of osteoporosis. In addition, the company has an early-stage pipeline focused on various disease areas. Alkermes has collaborations with Eli Lilly and Company; Amylin Pharmaceuticals, Inc.; Cephalon, Inc.; Indevus Pharmaceuticals, Inc.; and Janssen-Cilag. The company was founded in 1987 and is headquartered in Cambridge, Massachusetts.